Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erming Tian

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Virology|January 5, 2005
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Eliana Bignotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Haematologica|June 22, 2019
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myelomaAneta Mikulasova, Cody Ashby, Ruslana G Tytarenko, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Virology|January 5, 2005
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Eliana Bignotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Haematologica|June 22, 2019
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myelomaAneta Mikulasova, Cody Ashby, Ruslana G Tytarenko, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Pageof 5